This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Aviva (AV.) – The finance conglomerate has announced it will not cancel £450m of preference shares after shareholder backlash. The move was set to provide further cash returns to shareholders, however after threat of an FCA investigation, management has reneged on the plan.
Fevertree Drinks (FVR) – One of the founders of the drinks company has sold 3 million shares, twice the amount he previously stated he was looking to sell, at a 7% discount to yesterday’s closing price.
GlaxoSmithKline (GSK) – The pharma giant has withdrawn from purchasing Pfizer’s consumer healthcare division just one day after Reckitt Benckiser also withdrew from the race.
Next (NXT) – The high street retailer has announced profits fell by 24% after a year management hailed as ‘the worst in 25 years’. Having suffered as a result of currency valuation following the Brexit vote, the CEO claimed this error would not happen again with 98% of currency for 2018/19 secured. Management also noted it was very early in the year to be giving sales guidance by division.
Smiths Group (SMIN) – The engineer announces first half revenues fell, with free cash flow sharply lower, although reaffirmed 2018 outlook at constant FX. However, management warns FX to remain a headwind.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| CREST NICHOLSON | CRST | -2.9% | 2.2% | -3.8% |
| GLAXOSMITHKLINE | GSK | -1.7% | -0.6% | -2.0% |
| RECKITT BENCKISER | RB/ | 4.8% | 7.8% | 4.2% |
| TED BAKER | TED | -12.9% | -0.7% | -14.9% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research